KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial.

Naoki Inui, Takahito Suzuki, Kazuki Tanaka, Masato Karayama, Yusuke Inoue, Kazutaka Mori, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Shun Matsuura, Koji Nishimoto, Takashi Matsui, Kazuhiro Asada, Dai Hashimoto, Masato Fujii, Mitsuru Niwa, Masahiro Uehara, Hiroyuki Matsuda, Keigo Koda, Masaki Ikeda, Nao Inami, Yutaro Tamiya, Masato Kato, Hideki Nakano, Yasuaki Mino, Noriyuki Enomoto, Takafumi Suda

J Clin Oncol 42(23) 2780-2789

PMID38833659
PMCIDPMC11315403
DOI10.1200/JCO.24.00278
发表日期2024-06-04
入排依据:The trial is a randomized Phase III oncology study with a drug intervention and original results, but its primary and secondary efficacy endpoints are binary response rates (complete response, nausea-free), not time-to-event outcomes. Therefore, it does not meet the core eligibility criterion for a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR).
摘要

摘要

PURPOSE: We evaluated the efficacy and safety of antiemetic therapy with olanzapine, a neurokinin-1 receptor antagonist (RA), a 5-hydroxytryptamine-3 (5-HT3) RA, and dexamethasone for preventing chemotherapy-induced nausea and vomiting in patients receiving carboplatin-containing chemotherapy. PATIENTS AND METHODS: Chemotherapy-naïve patients scheduled to receive carboplatin (AUC ≥5) were randomly assigned to receive either olanzapine 5 mg once daily (olanzapine group) or placebo (placebo group) in combination with aprepitant, a 5-HT3 RA, and dexamethasone. The primary end point was the complete response (CR; no vomiting and no rescue therapy) rate in the overall phase (0-120 hours). Secondary end points included the proportion of patients free of nausea and safety. RESULTS: In total, 355 patients (78.6% male, median age 72 years, 100% thoracic cancer), including 175 and 180 patients in the olanzapine and placebo groups, respectively, were evaluated. The overall CR rate was 86.9% in the olanzapine group versus 80.6% in the placebo group. The intergroup difference in the overall CR rate was 6.3% (95% CI, -1.3 to 13.9). The proportions of patients free of chemotherapy-induced nausea in the overall (88.6% in the olanzapine group v 75.0% in the placebo group) and delayed (89.7% v 75.6%, respectively) phases were significantly higher in the olanzapine group than in the placebo group (both P < .001). Somnolence was observed in 43 (24.6%) and 41 (22.9%) patients in the olanzapine and placebo groups, respectively, and no events were grade ≥3 in severity. CONCLUSION: The addition of olanzapine was not associated with a significant increase in the overall CR rate. Regarding the prevention of nausea, adding olanzapine provided better control in patients receiving carboplatin-containing chemotherapy, which needs further exploration.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。